观点网讯:6月24日,眼科生物科技公司拨康视云正式启动港股招股,计划发行6058.2万股,其中10%为香港公开发售。每股定价10.1港元,每手500股对应入场费约5101港元,预计7月3日挂牌上市,建银国际及华泰国际担任联席保荐人。拨康视云专注于眼科疗法研发,核心产品CBT-001针对翼状胬肉治疗,已在中美启动三期临床试验;另一核心产品CBT-009用于青少年近视防治,去年7月向美国药管局提交临床...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.